​

Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

DCPH Stock Forecast

Deciphera Pharmaceuticals stock forecast is as follows: an average price target of $26.32 (represents a 2.85% upside from DCPH’s last price of $25.59) and a rating consensus of 'Hold', based on 10 wall street analysts offering a 1-year stock forecast.

DCPH Price Target

The average price target for Deciphera Pharmaceuticals (DCPH) is $26.32 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $25.00. This represents a potential 2.85% upside from DCPH's last price of $25.59.

DCPH Analyst Ratings

Hold

According to 10 Wall Street analysts, Deciphera Pharmaceuticals's rating consensus is 'Hold'. The analyst rating breakdown for DCPH stock is 0 'Strong Buy' (0.00%), 4 'Buy' (40.00%), 6 'Hold' (60.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Deciphera Pharmaceuticals Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 30, 2024Peter LawsonBarclays$26.00$25.272.89%1.60%
Apr 29, 2024Eun YangJefferies$25.60$25.301.21%0.04%
Apr 29, 2024Christopher RaymondRaymond James$25.00$25.29-1.15%-2.31%
Apr 29, 2024Christopher RaymondRaymond James$25.60$25.251.41%0.04%
Feb 07, 2023Leerink Partners$30.00$16.7179.53%17.23%
Jan 04, 2023Leerink Partners$28.00$15.9475.66%9.42%
Jan 04, 2023Barclays$9.00$15.94-43.54%-64.83%
Sep 12, 2022H.C. Wainwright$25.00$18.0838.27%-2.31%
Aug 05, 2022H.C. Wainwright$20.00$16.5820.63%-21.84%

The latest Deciphera Pharmaceuticals stock forecast, released on Apr 30, 2024 by Peter Lawson from Barclays, set a price target of $26.00, which represents a 2.89% increase from the stock price at the time of the forecast ($25.27), and a 1.60% increase from DCPH last price ($25.59).

Deciphera Pharmaceuticals Price Target by Period

1M3M12M
# Anlaysts--4
Avg Price Target--$25.55
Last Closing Price$25.59$25.59$25.59
Upside/Downside-100.00%-100.00%-0.16%

In the current month, the average price target of Deciphera Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Deciphera Pharmaceuticals's last price of $25.59. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Apr 29, 2024BarclaysUnderweightEqual-WeightUpgrade
Apr 29, 2024JMP SecuritiesMarket OutperformMarket PerformDowngrade
Apr 29, 2024GuggenheimBuyNeutralDowngrade
Apr 29, 2024JefferiesHoldDowngrade
Apr 29, 2024Piper SandlerOverweightNeutralDowngrade
Oct 30, 2023Piper SandlerOverweightUpgrade
Aug 10, 2023Raymond JamesBuyUpgrade
Feb 07, 2023SVB LeerinkOutperformOutperformHold
Jan 06, 2023JonesTradingHoldUpgrade
Jan 04, 2023William BlairOutperformInitialise
Jan 04, 2023SVB LeerinkOutperformOutperformHold
Jan 04, 2023BarclaysUnderweightUnderweightHold
Jan 04, 2023GuggenheimBuyUpgrade
Sep 12, 2022SVB LeerinkOutperformOutperformHold
Sep 12, 2022Wolfe ResearchBuyBuyHold
Aug 05, 2022JMP SecuritiesMarket OutperformUpgrade
Feb 28, 2022BarclaysUnderweightDowngrade

Deciphera Pharmaceuticals's last stock rating was published by Barclays on Apr 29, 2024. The company Upgrade its DCPH rating from "Underweight" to "Equal-Weight".

Deciphera Pharmaceuticals Financial Forecast

Deciphera Pharmaceuticals Revenue Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19
Revenue--------$48.29M--$33.45M$36.34M--$29.22M$24.20M--$25.16M$19.49M--$62.00K---
Avg Forecast$72.50M$62.53M$55.60M$50.40M$54.83M$53.33M$49.46M$46.20M$45.93M$39.45M$36.09M$35.69M$35.97M$33.08M$30.56M$26.88M$23.41M$23.47M$21.93M$22.46M$18.65M$6.71M$877.78K$56.98K$1.25M$454.55K$2.00M
High Forecast$72.50M$62.53M$55.60M$50.40M$54.83M$53.33M$51.95M$46.20M$47.26M$41.44M$36.09M$35.69M$35.97M$33.08M$30.56M$26.88M$23.41M$23.47M$21.93M$22.46M$18.65M$6.71M$877.78K$68.38K$1.25M$454.55K$2.00M
Low Forecast$72.50M$62.53M$55.60M$50.40M$54.83M$53.33M$45.19M$46.20M$42.94M$37.59M$36.09M$35.69M$35.97M$33.08M$30.56M$26.88M$23.41M$23.47M$21.93M$22.46M$18.65M$6.71M$877.78K$45.59K$1.25M$454.55K$2.00M
# Analysts111122557105544445121110109813655
Surprise %--------1.05%--0.94%1.01%--1.09%1.03%--1.12%1.04%--1.09%---

Deciphera Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 5 analysts is $46.20M, with a low forecast of $46.20M, and a high forecast of $46.20M. DCPH's average Quarter revenue forecast represents a -4.34% decrease compared to the company's last Quarter revenue of $48.29M (Dec 23).

Deciphera Pharmaceuticals EBITDA Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19
# Analysts111122557105544445121110109813655
EBITDA--------$-50.78M--$-53.26M$-47.16M--$-46.89M$-87.61M--$-60.37M$-61.79M--$-69.89M$-66.76M--
Avg Forecast$-72.50M$-62.53M$-55.60M$-50.40M$-54.83M$-53.33M$-49.46M$-61.99M$-45.93M$-39.45M$-36.09M$-56.36M$-95.08M$-33.08M$-30.56M$-51.23M$-23.41M$-23.47M$-21.93M$-60.57M$-18.65M$-6.71M$-877.78K$-65.98M$-1.25M$-454.55K$-2.00M
High Forecast$-72.50M$-62.53M$-55.60M$-50.40M$-54.83M$-53.33M$-45.19M$-49.59M$-42.94M$-37.59M$-36.09M$-45.08M$-76.07M$-33.08M$-30.56M$-40.99M$-23.41M$-23.47M$-21.93M$-48.45M$-18.65M$-6.71M$-877.78K$-52.78M$-1.25M$-454.55K$-2.00M
Low Forecast$-72.50M$-62.53M$-55.60M$-50.40M$-54.83M$-53.33M$-51.95M$-74.39M$-47.26M$-41.44M$-36.09M$-67.63M$-114.10M$-33.08M$-30.56M$-61.48M$-23.41M$-23.47M$-21.93M$-72.68M$-18.65M$-6.71M$-877.78K$-79.18M$-1.25M$-454.55K$-2.00M
Surprise %--------1.11%--0.95%0.50%--0.92%3.74%--1.00%3.31%--1.06%53.41%--

undefined analysts predict DCPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Deciphera Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Deciphera Pharmaceuticals Net Income Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19
# Analysts111122557105544445121110109813655
Net Income--------$-47.19M--$-45.96M$-45.94M--$-46.11M$-88.40M--$-61.30M$-62.74M--$-72.81M$-67.22M--
Avg Forecast$-27.09M$-36.41M$-40.78M$-43.69M$-44.25M$-43.43M$-46.25M$-63.04M$-50.70M$-53.25M$-54.18M$-57.31M$-95.93M$-50.37M$-57.49M$-52.10M$-120.52M$-108.68M$-100.93M$-61.30M$-101.05M$-113.53M$-119.46M$-66.40M$-100.69M$-99.42M$-96.74M
High Forecast$-27.09M$-36.41M$-40.78M$-43.69M$-44.25M$-43.43M$-37.84M$-50.43M$-43.70M$-48.89M$-54.18M$-45.85M$-76.74M$-50.37M$-57.49M$-41.68M$-120.52M$-108.68M$-100.93M$-49.04M$-101.05M$-113.53M$-119.46M$-53.12M$-100.69M$-99.42M$-96.74M
Low Forecast$-27.09M$-36.41M$-40.78M$-43.69M$-44.25M$-43.43M$-55.50M$-75.65M$-56.82M$-59.37M$-54.18M$-68.77M$-115.12M$-50.37M$-57.49M$-62.52M$-120.52M$-108.68M$-100.93M$-73.56M$-101.05M$-113.53M$-119.46M$-79.68M$-100.69M$-99.42M$-96.74M
Surprise %--------0.93%--0.80%0.48%--0.88%0.73%--1.00%0.62%--1.10%0.67%--

Deciphera Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. DCPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Deciphera Pharmaceuticals SG&A Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19
# Analysts111122557105544445121110109813655
SG&A--------$39.15M--$31.45M$32.20M--$28.32M$37.15M--$30.75M$30.07M--$23.94M$23.74M--
Avg Forecast$124.47M$107.36M$95.46M$86.53M$94.13M$91.56M$84.91M$38.08M$78.86M$67.73M$61.97M$34.61M$61.76M$56.80M$52.47M$46.14M$40.18M$40.29M$37.64M$38.56M$32.02M$11.51M$1.51M$97.83K$2.15M$780.39K$3.43M
High Forecast$124.47M$107.36M$95.46M$86.53M$94.13M$91.56M$89.18M$45.69M$81.14M$71.15M$61.97M$41.54M$61.76M$56.80M$52.47M$46.14M$40.18M$40.29M$37.64M$38.56M$32.02M$11.51M$1.51M$117.40K$2.15M$780.39K$3.43M
Low Forecast$124.47M$107.36M$95.46M$86.53M$94.13M$91.56M$77.59M$30.46M$73.72M$64.54M$61.97M$27.69M$61.76M$56.80M$52.47M$46.14M$40.18M$40.29M$37.64M$38.56M$32.02M$11.51M$1.51M$78.27K$2.15M$780.39K$3.43M
Surprise %--------0.50%--0.91%0.52%--0.61%0.92%--0.80%0.94%--244.66%11.06%--

Deciphera Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $38.08M, based on 5 Wall Street analysts, with a range of $30.46M to $45.69M. The forecast indicates a -2.74% fall compared to DCPH last annual SG&A of $39.15M (Dec 23).

Deciphera Pharmaceuticals EPS Forecast

Dec 25Oct 25Jul 25Mar 25Dec 24Oct 24Jul 24Mar 24Dec 23Oct 23Jul 23Mar 23Dec 22Oct 22Jul 22Mar 22Dec 21Oct 21Jul 21Mar 21Dec 20Oct 20Jul 20Mar 20Dec 19Oct 19Jul 19
# Analysts111122557105544445121110109813655
EPS-----------$-0.56$-0.60--$-0.79$-1.51--$-1.06$-1.11--$-1.36$-1.31--
Avg Forecast$-0.31$-0.42$-0.47$-0.50$-0.51$-0.50$-0.53$-0.55$-0.58$-0.61$-0.62$-0.59$-0.56$-0.58$-0.66$-0.90$-1.38$-1.24$-1.16$-1.07$-1.16$-1.30$-1.37$-1.25$-1.15$-1.14$-1.11
High Forecast$-0.31$-0.42$-0.47$-0.50$-0.51$-0.50$-0.43$-0.55$-0.50$-0.56$-0.62$-0.59$-0.56$-0.58$-0.66$-0.90$-1.38$-1.24$-1.16$-1.07$-1.16$-1.30$-1.37$-1.25$-1.15$-1.14$-1.11
Low Forecast$-0.31$-0.42$-0.47$-0.50$-0.51$-0.50$-0.64$-0.55$-0.65$-0.68$-0.62$-0.59$-0.56$-0.58$-0.66$-0.90$-1.38$-1.24$-1.16$-1.07$-1.16$-1.30$-1.37$-1.25$-1.15$-1.14$-1.11
Surprise %-----------0.94%1.08%--0.88%1.09%--0.99%0.96%--1.08%1.14%--

According to undefined Wall Street analysts, Deciphera Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to DCPH previous annual EPS of $NaN (undefined).

Deciphera Pharmaceuticals Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
AVDLAvadel Pharmaceuticals$10.73$30.00179.59%Buy
PROCProcaps Group$3.69$10.00171.00%
IRWDIronwood Pharmaceuticals$3.53$8.50140.79%Buy
EVOEvotec SE$4.78$8.0067.36%Buy
AMPHAmphastar Pharmaceuticals$40.85$66.0061.57%Buy
ANIPANI Pharmaceuticals$55.83$79.0041.50%Buy
COLLCollegium Pharmaceutical$30.90$42.3336.99%Buy
ALKSAlkermes$30.75$37.5021.95%Hold
NBIXNeurocrine Biosciences$136.69$156.1414.23%Buy
PBHPrestige Consumer Healthcare$80.39$89.5011.33%Buy
SUPNSupernus Pharmaceuticals$36.22$36.00-0.61%Buy
PAHCPhibro Animal Health$22.34$18.67-16.43%Buy

DCPH Forecast FAQ

Is Deciphera Pharmaceuticals a good buy?

No, according to 10 Wall Street analysts, Deciphera Pharmaceuticals (DCPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 40.00% of DCPH's total ratings.

What is DCPH's price target?

Deciphera Pharmaceuticals (DCPH) average price target is $26.32 with a range of $25 to $30, implying a 2.85% from its last price of $25.59. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Deciphera Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for DCPH stock, the company can go up by 2.85% (from the last price of $25.59 to the average price target of $26.32), up by 17.23% based on the highest stock price target, and down by -2.31% based on the lowest stock price target.

Can Deciphera Pharmaceuticals stock reach $40?

DCPH's average twelve months analyst stock price target of $26.32 does not support the claim that Deciphera Pharmaceuticals can reach $40 in the near future.

What are Deciphera Pharmaceuticals's analysts' financial forecasts?

Deciphera Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $203.82M (high $206.31M, low $199.55M), average EBITDA is $-220M (high $-203M, low $-234M), average net income is $-197M (high $-176M, low $-219M), average SG&A $308.68M (high $320.57M, low $293.75M), and average EPS is $-2.087 (high $-1.991, low $-2.193). DCPH's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $241.03M (high $241.03M, low $241.03M), average EBITDA is $-241M (high $-241M, low $-241M), average net income is $-148M (high $-148M, low $-148M), average SG&A $413.82M (high $413.82M, low $413.82M), and average EPS is $-1.693 (high $-1.693, low $-1.693).

Did the DCPH's actual financial results beat the analysts' financial forecasts?

Based on Deciphera Pharmaceuticals's last annual report (Dec 2023), the company's revenue was $163.36M, beating the average analysts forecast of $157.16M by 3.94%. Apple's EBITDA was $-211M, beating the average prediction of $-178M by 18.63%. The company's net income was $-195M, missing the average estimation of $-215M by -9.52%. Apple's SG&A was $136.46M, missing the average forecast of $243.17M by -43.88%. Lastly, the company's EPS was $0, missing the average prediction of $-2.403 by -100.00%. In terms of the last quarterly report (Dec 2023), Deciphera Pharmaceuticals's revenue was $48.29M, beating the average analysts' forecast of $45.93M by 5.14%. The company's EBITDA was $-50.782M, beating the average prediction of $-45.934M by 10.56%. Deciphera Pharmaceuticals's net income was $-47.19M, missing the average estimation of $-50.697M by -6.92%. The company's SG&A was $39.15M, missing the average forecast of $78.86M by -50.36%. Lastly, the company's EPS was $0, missing the average prediction of $-0.58 by -100.00%